"IC14 to enter clinical trials" means future Phase I, Xoma is far ahead.
"IC14 is an antibody blocks CD14" this is an approach leaa broad than Bpi, and more like (not identical)what E5, centoxin, Bayer, synergen tried and failed on. Of course, the final proof is the clinical trials, again they are going to begin Phase I. And, it could bring another combination posibility with Bpi in the future. The other failure candidates will probably be reinvestigated once there is one of them approved. Bpi will be the first (caveat, my wish).
Psoriasis trial is a phase I, going into Phase I/II (meaning phase I again). Xoma/GNE Phase II is completed, next step is III, if they have good data, last press release in the subject seems like yes they do.
Again, xoma is ahead. Ligand is the main thread, their product is a small moecule for oral delivery (vs xoma's and Icos' monoclonal antibodies which are usually for intramuscular injection), if effective Lgnd's will be the easy leader, they are in phase I.
|
